<SEC-DOCUMENT>0001269026-15-000012.txt : 20150818
<SEC-HEADER>0001269026-15-000012.hdr.sgml : 20150818
<ACCEPTANCE-DATETIME>20150804085949
ACCESSION NUMBER:		0001269026-15-000012
CONFORMED SUBMISSION TYPE:	8-K
PUBLIC DOCUMENT COUNT:		3
CONFORMED PERIOD OF REPORT:	20150804
ITEM INFORMATION:		Other Events
ITEM INFORMATION:		Financial Statements and Exhibits
FILED AS OF DATE:		20150804
DATE AS OF CHANGE:		20150804

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			AMEDICA Corp
		CENTRAL INDEX KEY:			0001269026
		STANDARD INDUSTRIAL CLASSIFICATION:	SURGICAL & MEDICAL INSTRUMENTS & APPARATUS [3841]
		IRS NUMBER:				000000000
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		8-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-33624
		FILM NUMBER:		151024150

	BUSINESS ADDRESS:	
		STREET 1:		1885 WEST 2100 STREET
		CITY:			SALT LAKE CITY
		STATE:			UT
		ZIP:			84119
		BUSINESS PHONE:		801-839-3516

	MAIL ADDRESS:	
		STREET 1:		1885 WEST 2100 STREET
		CITY:			SALT LAKE CITY
		STATE:			UT
		ZIP:			84119

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	AMEDICA CORP
		DATE OF NAME CHANGE:	20031104
</SEC-HEADER>
<DOCUMENT>
<TYPE>8-K
<SEQUENCE>1
<FILENAME>a201508038k.htm
<DESCRIPTION>8-K
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd">
<html>
	<head>
		<!-- Document created using Wdesk 1 -->
		<!-- Copyright 2015 Workiva -->
		<title>2015.08.03_8-K - Press Release</title>
	</head>
	<body style="font-family:Times New Roman;font-size:10pt;">
<a name="sdf62f2f4df0945cc9e5535a262023c27"></a><div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><br><div style="line-height:120%;text-align:center;font-size:18pt;"><font style="font-family:inherit;font-size:18pt;font-weight:bold;">UNITED STATES</font></div><div style="line-height:120%;text-align:center;font-size:18pt;"><font style="font-family:inherit;font-size:18pt;font-weight:bold;">SECURITIES AND EXCHANGE COMMISSION</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">WASHINGTON, D.C. 20549</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;"><hr></div><div style="line-height:120%;padding-bottom:13px;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;text-align:center;font-size:18pt;"><font style="font-family:inherit;font-size:18pt;font-weight:bold;">FORM&#160;8-K</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">CURRENT REPORT</font></div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">Pursuant to Section&#160;13 or 15(d)&#160;of the</font></div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">Securities Exchange Act of 1934</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Date of report (Date of earliest event reported): August 4, 2015</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;text-align:center;font-size:18pt;"><font style="font-family:inherit;font-size:18pt;font-weight:bold;">Amedica Corporation</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(Exact name of registrant as specified in its charter)</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="5"></td></tr><tr><td width="32%"></td><td width="2%"></td><td width="32%"></td><td width="2%"></td><td width="32%"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Delaware</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:1pt;"><font style="font-family:inherit;font-size:1pt;font-weight:bold;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">001-33624</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:1pt;"><font style="font-family:inherit;font-size:1pt;font-weight:bold;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">84-1375299</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(State or other jurisdiction</font></div><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">of incorporation)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:1pt;"><font style="font-family:inherit;font-size:1pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(Commission</font></div><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">File Number)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:1pt;"><font style="font-family:inherit;font-size:1pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(IRS Employer</font></div><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Identification No.)</font></div></td></tr></table></div></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="3"></td></tr><tr><td width="49%"></td><td width="2%"></td><td width="49%"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">1885 West 2100 South</font></div><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Salt Lake City, UT</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:1pt;"><font style="font-family:inherit;font-size:1pt;font-weight:bold;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">84119</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(Address of principal executive offices)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:1pt;"><font style="font-family:inherit;font-size:1pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(Zip Code)</font></div></td></tr></table></div></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Registrant&#8217;s telephone number, including area code: </font><font style="font-family:inherit;font-size:10pt;font-weight:bold;">(801) 839-3500</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(Former Name or Former Address, if Changed Since Last Report)</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Check the appropriate box below if the Form&#160;8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (</font><font style="font-family:inherit;font-size:10pt;text-decoration:underline;">see</font><font style="font-family:inherit;font-size:10pt;">&#32;General Instruction A.2. below):</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;text-align:left;padding-left:24px;text-indent:-24px;font-size:10pt;"><font style="font-family:Wingdings;font-size:10pt;">o</font><font style="font-family:inherit;font-size:10pt;">&#160; Written communications pursuant to Rule&#160;425 under the Securities Act (17 CFR 230.425)</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;text-align:left;padding-left:24px;text-indent:-24px;font-size:10pt;"><font style="font-family:Wingdings;font-size:10pt;">o</font><font style="font-family:inherit;font-size:10pt;">&#160; Soliciting material pursuant to Rule&#160;14a-12 under the Exchange Act (17 CFR 240.14a-12)</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;text-align:left;padding-left:24px;text-indent:-24px;font-size:10pt;"><font style="font-family:Wingdings;font-size:10pt;">o</font><font style="font-family:inherit;font-size:10pt;">&#160; Pre-commencement communications pursuant to Rule&#160;14d-2(b)&#160;under the Exchange Act (17 CFR 240.14d-2(b))</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;text-align:left;padding-left:24px;text-indent:-24px;font-size:10pt;"><font style="font-family:Wingdings;font-size:10pt;">o</font><font style="font-family:inherit;font-size:10pt;">&#160; Pre-commencement communications pursuant to Rule&#160;13e-4(c)&#160;under the Exchange Act (17 CFR 240.13e-4(c))</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;text-align:left;font-size:1pt;"><font style="font-family:inherit;font-size:1pt;">&#160;</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;"><hr></div><br><div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><hr style="page-break-after:always"><a name="sdf62f2f4df0945cc9e5535a262023c27"></a><div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><br><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Item 8.01 Other Events.  </font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">On August 4, 2015, Amedica Corporation issued a press release announcing that all four submissions to the International Society for Technology in Arthroplasty (&#8220;ISTA&#8221;) were accepted for presentation during the 28th annual congress occurring September 30 - October 3, 2015 in Vienna, Austria.  A copy of the press release is attached hereto as Exhibit 99.1 and is incorporated herein by reference.</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Item 9.01 Financial Statements and Exhibits.</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(d)&#160;&#160;&#160;&#160;&#160; Exhibits.</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">99.1&#160;&#160;&#160;&#160;Amedica Corporation Press Release dated August 4, 2015.</font></div><div style="line-height:174%;text-align:left;padding-left:48px;text-indent:-48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">SIGNATURE</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.</font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:91.40625%;border-collapse:collapse;text-align:left;"><tr><td colspan="2"></td></tr><tr><td width="50%"></td><td width="50%"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:1pt;"><font style="font-family:inherit;font-size:1pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">AMEDICA CORPORATION</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Date: August 4, 2015</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">/s/ Ty Lombardi</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:1pt;"><font style="font-family:inherit;font-size:1pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Ty Lombardi</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:1pt;"><font style="font-family:inherit;font-size:1pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Vice President, Finance </font></div></td></tr></table></div></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><br><div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div>	</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.1
<SEQUENCE>2
<FILENAME>a20150803991.htm
<DESCRIPTION>EXHIBIT 99.1
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd">
<html>
	<head>
		<!-- Document created using Wdesk 1 -->
		<!-- Copyright 2015 Workiva -->
		<title>2015.08.03_Ex 99.1 - Press Release</title>
	</head>
	<body style="font-family:Times New Roman;font-size:10pt;">
<a name="s49c60dac10424673b709ba86b505d8d7"></a><div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><br><div style="line-height:120%;text-align:right;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;font-weight:bold;">Exhibit 99.1</font></div><div style="line-height:120%;text-align:left;padding-left:24px;text-indent:0px;"><img src="amedica.gif" style="height:89px;width:165px;"></div><div style="line-height:120%;text-align:center;font-size:14pt;"><font style="font-family:inherit;font-size:14pt;font-weight:bold;">Amedica to Present Research Supporting Femoral Head Development at the International Society for Technology in Arthroplasty </font></div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-style:italic;">Four Scientific Presentations Demonstrate Superiority of Silicon Nitride over Existing Ceramics</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">SALT LAKE CITY,&#160;August 4, 2015 -&#160;Amedica Corporation&#160;(Nasdaq:AMDA), an innovative biomaterial company which develops and manufactures silicon nitride as a platform for biomedical applications, is pleased to announce all four submissions to the International Society for Technology in Arthroplasty (&#8220;ISTA&#8221;) were accepted for presentation during the 28</font><font style="font-family:inherit;font-size:11pt;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">th</sup></font><font style="font-family:inherit;font-size:11pt;">&#32;annual congress occurring September 30 - October 3, 2015 in Vienna, Austria.  </font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">&#8220;Our presentations will demonstrate the rationale for using silicon nitride in total hip ceramic bearings,&#8221; said Dr. Sonny Bal, chairman and CEO of&#160;Amedica Corporation. &#8220;Our scientific data will convincingly demonstrate the serious limitations of other existing ceramics, while highlighting the advantages of silicon nitride, even as we begin testing of our femoral head product.  I&#8217;m very proud of our continued innovation and robust science, which will be presented at this important scientific forum.&#8221;</font></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font></div><div style="line-height:120%;text-align:justify;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">Accepted submission titles and their authors include: </font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:11pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;font-style:italic;">Debunking the Myth That Ceramics Are Bioinert: Comparison of Alumina versus Silicon Nitride</font><font style="font-family:inherit;font-size:11pt;">&#32;- B. Sonny Bal&#894; Bryan McEntire&#894; Mohamed Rahaman&#894; Giuseppe Pezzotti</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:11pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;font-style:italic;">The Effect of Accelerated Aging on the Material Properties of Ceramic Femoral Heads</font><font style="font-family:inherit;font-size:11pt;">&#32;- Bryan McEntire&#894; B. Sonny Bal&#894; Mohamed Rahaman&#894; Giuseppe Pezzotti</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:11pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;font-style:italic;">Surface Modulation of Silicon Nitride Ceramics for Orthopaedic Applications</font><font style="font-family:inherit;font-size:11pt;">&#32;- Ryan Bock&#894; Bryan McEntire&#894; B. Sonny Bal&#894; Mohamed Rahaman&#894; Marco Boffelli&#894; Giuseppe Pezzotti</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:11pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;font-style:italic;">The Effect of Ceramic Femoral Head Material Composition on Polyethylene Structure and Oxidation in Total Hip Bearings</font><font style="font-family:inherit;font-size:11pt;">&#32;- Giuseppe Pezzotti&#894; Leonardo Puppulin&#894; Marco Boffelli&#894; Bryan McEntire&#894; Mohamed Rahaman&#894; Kengo Yamamoto&#894; B. Sonny Bal</font></div></td></tr></table><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">ISTA is an annual congress focused exclusively on arthroplasty and attracts the field&#8217;s leading surgeons, researchers and device makers from around the world. Of the more than 700 abstracts submitted for presentation approval at the annual congress, ISTA and its reviewers selected all four of the Company&#8217;s submissions. </font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">About&#160;Amedica Corporation</font></div><div style="line-height:120%;text-align:justify;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">Amedica is focused on the development and application of medical-grade silicon nitride ceramics. Amedica markets spinal fusion products and is developing a new generation of wear- and corrosion-resistant implant components for hip and knee arthroplasty. The Company manufactures its products in its ISO 13485 certified manufacturing facility and, through its partnership with Kyocera, the world's largest ceramic manufacturer. Amedica's spine products are FDA-cleared, CE-marked, and are currently marketed in the U.S. and select markets in Europe and South America through its distributor network and its growing OEM partnerships.</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;font-weight:bold;">For more information </font><font style="font-family:inherit;font-size:11pt;">on Amedica or its silicon nitride material platform, please visit&#160;</font><font style="font-family:inherit;font-size:11pt;color:#0000ff;text-decoration:underline;">www.amedica.com</font><font style="font-family:inherit;font-size:11pt;">.</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">About ISTA</font></div><div style="line-height:120%;text-align:justify;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">ISTA is a non-profit organization dedicated to advancing the art and science of joint replacement around the world. Every year the organization hosts a congress where the best clinicians, engineers, researchers, and industry members from across the globe come together to present and discuss leading edge work in the field of arthroplasty.</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">Forward-Looking Statements</font></div><br><div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><hr style="page-break-after:always"><a name="s49c60dac10424673b709ba86b505d8d7"></a><div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><br><div style="line-height:120%;text-align:justify;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">This press release contains statements that constitute forward-looking statements within the meaning of the Securities Act of 1933 and the Securities Exchange Act of 1934, as amended by the Private Securities Litigation Reform Act of 1995. Forward-looking statements contained in this press release include the intent, belief or current expectations of Amedica of the impact of new scientific data with respect to silicon nitride in total hip ceramic bearings.  Such forward-looking statements are subject to risks and uncertainties such as the timing and success of new product introductions, FDA review and clearance, physician acceptance, endorsement, and use of Amedica's products, regulatory matters, competitor activities, changes in and adoption of reimbursement rates, potential product recalls, effects of global economic conditions and changes in foreign currency exchange rates. Other factors that could cause actual results to differ materially from those contemplated within this press release can also be found in Amedica's Risk Factors disclosure in its Annual Report on Form 10-K, filed with the Securities and Exchange Commission (SEC) on March 24, 2015, and in Amedica's other filings with the SEC.  Forward-looking statements contained in this press release speak only as of the date of this press release. We undertake no obligation to update any forward-looking statements as a result of new information, events or circumstances or other factors arising or coming to our attention after the date hereof.</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">Contact:</font></div><div style="line-height:120%;text-align:left;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">Mike Houston</font></div><div style="line-height:120%;text-align:left;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">VP, Commercialization &amp; Communications</font></div><div style="line-height:120%;text-align:left;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">801-839-3534</font></div><div style="line-height:120%;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;color:#0000ff;text-decoration:underline;">mhouston@amedica.com</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><br><div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div>	</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>3
<FILENAME>amedica.gif
<TEXT>
begin 644 amedica.gif
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M^O?X\?7Y^_GV\?WZ\_[^_B'_"TY%5%-#05!%,BXP P$!   A^00      "P
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MY HX^<FVM0B($0((!6C PQ(QL46P2V"6T&$!$2BF?!'0VM-$80 7H"<Z-&"
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MP# (DZ!+OK"'95 $IA<%=_ .WE $>D (;9 %SX &8: -97 "RA *4B -_WZ
M"" Y!L_P!EO@C*7'"P-Q#W^ ".$0F=G0"85P"BOP",$@!9/@#5G@"\$PE-!P
M!F+ #?.0#Y]0!+I@#+T@C5:I HCP#'N0!=L@!U? #,VP!V&P#&80!KV@"]$0
M#FGP!=%YA3/@"-\  X@ #7]P!=10BJJ F(- !8B #L' "(2P"VLXA'QX!8!P
M!B 0!O;X"7YH5,FY!XAPB(;P#]]0!;QPF<B !)&8"E?P#$_@ 5^PAA=)![I
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3[-N^[ON^\!N_\CN_]%M  0$ .P$!

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
